Financing ·
MoonLake Immunotherapeutics entered into an underwriting agreement with Leerink Partners LLC to issue and sell…
MLTXMoonLake Immunotherapeutics
MoonLake Immunotherapeutics entered into an underwriting agreement with Leerink Partners LLC to issue and sell 9,000,000 Class A ordinary shares at $20.00 per share and up to 1,000,000 pre-funded warrants at $19.9999 per warrant. The gross proceeds from the offering is expected to offering $200 million. The offering is expected to close on June 25, 2026. MoonLake Immunotherapeutics is a biotechnology company focused on developing immunologicals for inflammatory diseases.